iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
Research TIGIT

iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020

Cambridge, MA and Gosselies, Belgium – June 15, 2020. iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today that it will present preclinical data for its investigational FcγR-engaging anti-TIGIT antibody, EOS-448, in a virtual poster presentation at the upcoming American Association of Cancer Research II (AACR II) Virtual Annual Meeting 2020 taking place June 22-24th. iTeos Therapeutics enrolled the first patient in its Phase 1/2 clinical trial with EOS-448 in solid tumors in February 2020.

The abstract and video presentation details are as follows:

Title: Preparation of a clinical trial with a-TIGIT antagonist antibody EOS-448, which demonstrates potent preclinical activity and safe toxicology profile

Session: Immune Checkpoints 4
Abstract #: 3720

Poster #: 3161
Authors: Thi Lien-Anh Nguyen, et al.

The abstract was posted online at 12:01 a.m. EDT on Friday, May 15 on the AACR conference website.

The e-poster website will be launched on June 22, the first day of the AACR Virtual Annual Meeting II. All e-posters will be made available for browsing on this date.

About iTeos Therapeutics

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. In April 2020, the Company closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. 

For further information, please contact:

Michel Detheux, CEO

iTeos Therapeutics, Inc.

info@iteostherapeutics.com

 

Amber Fennell, Paul Kidwell

Consilium Strategic Communications

+44 203 709 5700

iteos@consilium-comms.com

 

Sarah McCabe and Zofia Mita

Stern Investor Relations, Inc.

+ 1 212 362 1200

iTeos@sternir.com

Related news

  • iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
    Clinical Trials Research TIGIT

    iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

    – First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials – – Initial clinical data expected in 1H 2021 – Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today that it has enrolled the first patient in its Phase 1/2 study with EOS884448 (EOS-448), the company’s investigational ADCC-enabled antagonist anti-TIGIT antibody drug candidate. Michel Detheux, PhD, President and Chief Executive Officer of iTeos, commented: “EOS-448 is an ADCC-enabled antagonist anti-TIGIT antibody that has been designed to maximize the therapeutic benefit of blocking TIGIT checkpoint inhibitors while engaging Fcγ receptors. The importance of TIGIT as a target for next-generation immunotherapy is becoming increasingly apparent in our field and, alongside our best-in-class adenosine A2A receptor antagonist EOS-850, iTeos now has two highly innovative immunotherapy programs in clinical development for patients suffering with advanced cancers.” Joanne Lager, M.D., Chief Medical Officer of iTeos, added, “ADCC-enabled antagonist anti-TIGIT programs are emerging as promising new immuno-oncology therapies. In preclinical studies, EOS-448 promotes anti-tumor immunity both alone and in combination with other oncology therapies. We believe it is well-positioned to provide important new therapeutic options for cancer patients. We look forward to evaluating EOS-448 in our now initiated Phase 1/2 trial and to reporting initial safety and efficacy results in the first half of 2021.” About the EOS-448 Phase 1/2 Trial This Phase 1/2 study of EOS-448 is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers. Participants’ tumors will be sampled before treatment and during treatment, to identify and confirm biomarkers to be used in further clinical development. Following dose escalation and determination of the recommended Phase 2 dose, the study design allows for the seamless expansion of patient cohorts to evaluate the anti-tumor activity of EOS-448 in specific tumor types. The trial will be conducted at multiple clinical sites in Europe and is expected to enroll approximately 30 patients with advanced cancer in the dose escalation portion. About TIGIT and EOS-448 TIGIT is an immune checkpoint inhibitor, which interacts with CD155 expressed on antigen-presenting cells or tumor cells to down-regulate T cell and Natural Killer (NK) cell functions. EOS-448 is a novel fully human IgG1 mAb against the TIGIT receptor to treat a wide range of tumor types expressing ligands of TIGIT and/or being infiltrated by TIGIT expressing immune cells. EOS-448 was designed to encompass multiple mechanisms to activate anti-tumor immunity, not only by restoring T cell effector functions, but also by depleting immunosuppressive Tregs or inducing direct cytotoxicity of TIGIT-expressing tumor cells and creating local inflammation by engaging Fcγ receptors on effector cells. During preclinical development, EOS-448 demonstrated potent competition with TIGIT-ligand binding as well as in vitro and ex-vivo ability to restore T cell function in human samples. EOS-448 has also confirmed preferred direct cytotoxicity on regulatory T cells when tested in human cancer samples and demonstrated a clean toxicity profile. EOS-448 has also demonstrated potent anti-tumor efficacy in a humanized mouse tumor model. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com  

  • iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
    Clinical Trials Corporate Research TIGIT

    iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020

    – EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020 – – EOS-448 has shown potent antitumor activity and a favourable tolerability profile in preclinical studies –   Cambridge, MA and Gosselies, Belgium – June 22, 2020. iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, is presenting preclinical data for its investigational FcγR-engaging anti-TIGIT antibody, EOS-448, in a virtual poster presentation at the American Association of Cancer Research II (AACR II) Virtual Annual Meeting 2020, taking place June 22-24th. EOS-448 has demonstrated strong functional activity and a clean safety profile in its preclinical studies. iTeos enrolled the first patient in the dose escalation portion of its Phase 1/2a study with EOS-448 in February, 2020. “We are excited to have started the Phase 1 portion of our first-in-human studies with our  FcγR-engaging anti-TIGIT antibody, EOS-448, which has demonstrated strong antitumor activity both as single agent and in combination as well as a clean tolerability profile in preclinical studies,” said Michel Detheux, Chief Executive Officer of iTeos Therapeutics. “We believe EOS-448 has significant potential to be beneficial to cancer patients in the clinic, on the basis of its potent activity in restoring antitumor immunity in preclinical studies, supported by its multiple mechanisms of action, as well as by the latest clinical data reported for compounds of the same class.” Summary of the Data to be Presented EOS-448, a novel FcγR-engaging anti-TIGIT antibody, is shown to be highly potent and demonstrates strong anti-tumor activity and a clean safety profile in the preclinical setting. In addition to its ability to reverse immunosuppression of NK and effector T cells, EOS-448 is an IgG1 antibody, and has been able to induce potent and preferential cytotoxicity directed against Tregs as compared to CD4 and CD8 effector cells. Characterization of cell populations show that tumor-infiltrating Tregs exhibit differentially high levels of TIGIT, making these cells preferentially susceptible to ADCC. Furthermore, among tumor-infiltrating lymphocytes, or TILs, CD4 and CD8 T cells  expressing high levels of TIGIT typically display an exhausted profile. In preclinical tumor models of pre-established tumors, EOS-448 demonstrated strong tumor growth delay activity as a single agent and when combined with anti-PD-1 antibody, further increased the antitumor activity and resulted in complete responses in seven out of eight mice. The observed antitumor activity correlated with an increase of IFNγ-secreting CD4 and CD8 T cells and preferential Treg depletion within the tumor microenvironment. When the same anti-TIGIT clone was built on an antibody isotype with low FcγR binding capabilities and tested in the same model, or when our anti-TIGIT EOS-448 was dosed in FcγR knockout mice, antitumor activity was lost demonstrating the key role of FcγR engagement for the therapeutic activity of anti-TIGIT therapies. When tested in NHP, EOS-448 demonstrated a dose-proportional increase in exposure with a classical human IgG1 profile. The increase in exposure correlated with increased target engagement. We observed full occupancy of the TIGIT receptor which was maintained for at least 1 week at the highest tested dose. EOS-448 was shown to have a favorable tolerability profile  in these preclinical toxicology studies, and the NOAEL was the highest tested dose of 10mg/kg. The abstract and video presentation details are as follows: Title: Preparation of a clinical trial with a-TIGIT antagonist antibody EOS-448, which demonstrates potent preclinical activity and safe toxicology profile Session:  Immune Checkpoints 4 Abstract #: 3720 Poster #: 3161 Authors: Thi Lien-Anh Nguyen, et al. The abstract was posted online at 12:01 a.m. EDT on Friday, May 15 on the AACR conference website. The e-poster website will be launched today, June 22, the first day of the AACR Virtual Annual Meeting II. All e-posters will be made available for browsing on this date. EOS-448 Clinical Development (ClinicalTrials.gov Trial Identifier: NCT04335253) This Phase 1/2a study of EOS-448 is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers. Participants’ tumors will be sampled before treatment and during treatment, to identify and confirm biomarkers to be used in further clinical development. Following dose escalation and determination of the recommended Phase 2 dose, the study design allows for the seamless expansion of patient cohorts to evaluate the anti-tumor activity of EOS-448 in specific tumor types. The trial will be conducted at multiple clinical sites in Europe and is expected to enroll approximately 30 patients with advanced cancer represented in the dose escalation portion. About iTeos Therapeutics iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. In April 2020, the Company  closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.  For further information, please contact:   Michel Detheux, CEO iTeos Therapeutics Inc info@iteostherapeutics.com   Amber Fennell, Paul Kidwell Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe, Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com  

  • iTeos Therapeutics Strengthens Leadership Team
    Corporate Financial Research

    iTeos Therapeutics Strengthens Leadership Team

    – Matthew Gall joins as Chief Financial Officer   – Dr Yvonne McGrath joins as Vice President of R&D  – Philippe Brantegem joins as Vice President of Human Resources  Cambridge, MA and Gosselies, Belgium – June 9, 2020 – iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today the appointments of Matthew Gall as Chief Financial Officer, Dr. Yvonne McGrath as Vice President of R&D and Philippe Brantegem as Vice President of Human Resources. “Matthew, Yvonne and Philippe are important additions to the growing iTeos Therapeutics leadership team and their unique skills and breadth and depth of experience will undoubtedly help to progress our pipeline, including our adenosine A2A receptor antagonist (EOS-850) and our anti-TIGIT antibody (EOS-448) programs, and position the company well for accelerated growth in the years to come,” said Michel Detheux, Chief Executive Officer of iTeos Therapeutics. “I am excited to join the iTeos team at this important time in the company’s growth. The talented personnel, highly differentiated immuno-oncology therapeutics and strong investors, position the company well as we pursue new treatments for people living with cancer,” said the new Chief Financial Officer of iTeos Therapeutics, Matthew Gall. Matthew Gall joins iTeos Therapeutics from Sarepta Therapeutics, Inc. where he was the Senior Vice President of Corporate Development and Treasurer. At Sarepta, Matthew led the Company’s recent multibillion partnership deal with Roche, and during his tenure, he oversaw the Company’s financial strategy and helped raise over $2 billion in capital. During his 15-year career in biotech, Matthew also worked at Celgene Corporation and Gilead Sciences in various roles including financial management and business development. Matthew holds an MBA from the University of Chicago Booth School of Business. Dr. Yvonne McGrath joins iTeos Therapeutics from Complix N.V. where she served as the Chief Scientific Officer. Yvonne has worked in the biotech industry for over 20 years, including a position as Head of Development at Immunocore, in addition to R&D management positions at Medigene and Biovex. Yvonne holds a Ph.D. from the University of Wales, College of Medicine, UK. Philippe Brantegem has delivered human resources support to biopharmaceutical companies such as Merck Sharp & Dohme, Besins Healthcare, Sanofi Pasteur MSD and Korn Ferry for over 20 years. Philippe holds master’s degrees in human resource management from the Université Libre de Bruxelles and in public administration from the Solvay Business School. About iTeos Therapeutics iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. In April 2020, the Company closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com.   Michel Detheux, CEO iTeos Therapeutics, Inc. info@iteostherapeutics.com   Amber Fennell, Paul Kidwell Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. +1 212 362 1200 iTeos@sternir.com